Pfizer acquires Embrex, re-entering poultry market

Published on February 15, 2007
information-circle This article is more than 3 years old

Pfizer Animal Health has acquired Embrex Inc., a biotechnology company in the poultry industry that created an in-ovo system for vaccine delivery, for $155 million.

Embrex, which has headquarters in Durham, N.C., reported revenues of $52.5 million in 2005. More than 80 percent of the poultry in North America receive vaccination against Marek's disease through the company's in-ovo system. Embrex also is active in developing new poultry vaccines and vaccine-delivery technologies.

Pfizer Animal Health of New York, N.Y., reported sales of $2.2 billion for 2005. The company develops and markets medicines and vaccines for beef and dairy cattle, swine, cats, dogs, and horses. Pfizer has not served the poultry market since selling off its feed-additive business in 2000.